IceCure Medical Ltd (ICCM) Regains Nasdaq Compliance

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a notification letter from Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Rule").

The Nasdaq staff made this determination of compliance with the Rule after the Company's ordinary shares was at a minimum closing bid price of $1.00 or more for at least 10 consecutive business days prior to the date of the notice. Accordingly, the Company has regained compliance with the Rule and Nasdaq considers the prior bid price deficiency matter now closed.

IceCure is now in full compliance with all Nasdaq continued listing requirements and will continue to be listed and traded on The Nasdaq Capital Market.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• Seagate board member Arumugavelu to step down at annual meeting
• Bank of America to redeem CAD1.425 billion in Canadian senior notes